Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14338424 | 0.63 | ALDH1A1 (0.36) | ALDH1A1HPGDSMN1; SMN2TSHR | |
| SCHEMBL16163601 | 0.58 | ALDH1A1 (0.41) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL5032078 | 0.58 | MAP4K1 (0.37) | ALDH1A1HPGDSMN1; SMN2TSHRMAP4K1 | |
| SCHEMBL21853414 | 0.57 | NCOA1 (0.35) | TSHRMAP4K1 | |
| SCHEMBL1004649 | 0.57 | ALDH1A1 (0.73) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL12221612 | 0.57 | SMN1; SMN2 (0.52) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL197079 | 0.57 | — | — | |
| SCHEMBL12987896 | 0.55 | — | — | |
| SCHEMBL12527238 | 0.55 | — | — | |
| SCHEMBL15218734 | 0.54 | HDAC6 (0.40) | ALDH1A1HPGDSMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552183-B2 | Process for the covalent coupling of two molecules by means of a diels-alder reaction with inverse electron requirement | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2013-10-08 | — | — | US | disclosed |
| US-8552183-B2 | Process for the covalent coupling of two molecules by means of a diels-alder reaction with inverse electron requirement | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2013-10-08 | — | — | US | disclosed |
| US-20100016545-A1 | PROCESS FOR THE COVALENT COUPLING OF TWO MOLECULES BY MEANS OF A DIELS-ALDER REACTION WITH INVERSE ELECTRON REQUIREMENT | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2010-01-21 | — | — | US | disclosed |
| US-20100016545-A1 | PROCESS FOR THE COVALENT COUPLING OF TWO MOLECULES BY MEANS OF A DIELS-ALDER REACTION WITH INVERSE ELECTRON REQUIREMENT | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2010-01-21 | — | — | US | disclosed |
| WO-2007144200-A1 | PROCESS FOR THE COVALENT COUPLING OF TWO MOLECULES BY MEANS OF A DIELS-ALDER REACTION WITH INVERSE ELECTRON REQUIREMENT | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2007-12-21 | — | — | WO | disclosed |
| EP-1867638-A1 | Procedure for the Conection of two Molecules via Diels-Alder Reactions with Inverse Electron Demand | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016545-A1 | PROCESS FOR THE COVALENT COUPLING OF TWO MOLECULES BY MEANS OF A DIELS-ALDER REACTION WITH INVERSE ELECTRON REQUIREMENT | CX3CR1, NR3C2, NR4A2 | ALDH1A1 2312/4885HPGD 2290/4885SMN1; SMN2 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.